TY - JOUR T1 - Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients JF - J Hepatol Y1 - 2017 A1 - Stanislas Pol A1 - Bourliere, Marc A1 - Lucier, Sandy A1 - et, al ED - Christophe Hézode ED - Dorival, Celine ED - Larrey, Dominique ED - Bronowicki, Jean-Pierre ED - Ledinghen, Victor D. E. ED - Zoulim, Fabien ED - Tran, Albert ED - Metivier, Sophie ED - Zarski, Jean-Pierre ED - Samuel, Didier ED - Guyader, Dominique ED - P. Marcellin ED - Minello, Anne ED - Alric, Laurent ED - Thabut, Dominique ED - Chazouilleres, Olivier ED - Riachi, Ghassan ED - Bourcier, Valerie ED - Mathurin, Philippe ED - Loustaud-Ratti, Veronique ED - D'Alteroche, Louis ED - Fouchard-Hubert, Isabelle ED - Habersetzer, Francois ED - Causse, Xavier ED - Geist, Claire ED - Rosa, Isabelle ED - Gournay, Jerome ED - Saillard, Eric ED - Billaud, Eric ED - Petrov-Sanchez, Ventzislava ED - Diallo, Alpha ED - Fontaine, Helene ED - Carrat, Fabrice KW - Chronic hepatitis C KW - Cirrhosis KW - daclatasvir KW - Direct antiviral agents KW - genotype 1 KW - Hepather cohort KW - Severe fibrosis KW - sofosbuvir KW - treatment VL - 66 SP - 39-47 IS - 1 ER -